Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics
(PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin +
etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+)
ES-SCLC.